Skip to main content
. 2021 Jan 15;10(1):156. doi: 10.3390/cells10010156

Figure 4.

Figure 4

MRGPRX2 mutations rendered the receptor unresponsiveness to rocuronium. (A) Snake diagram of MRGPRX2 indicating three missense mutations identified in the patient. (B) RBL-MRGPRX2 were stimulated with different concentrations of rocuronium for 30 min, and β-hexosaminidase release was determined. (C) Untransfected WT RBL-2H3 cells were stimulated with rocuronium (2 mg/mL) for 30 min, and β-hexosaminidase release was determined. (D) Cell surface expression of WT MRGPRX2 and its variants was determined by flow cytometry. (E) Cells expressing WT MRGPRX2 and its variants were exposed to buffer (control) or rocuronium (1 mg/mL) for 30 min, and β-hexosaminidase release was determined. (F) Dose response of rocuronium-induced β-hexosaminidase release was determined in cells expressing WT MRGPRX2 and M196I. Data are the mean ± SEM of at least three experiments. For comparisons of two samples, two-tailed unpaired t-test was used. For comparisons of multiple samples to a control group, one-way ANOVA with Dunnett’s post-hoc test was used. ** p < 0.01, *** p < 0.001 and **** p < 0.0001.